The Asia Pacific drug modelling software market is expected to reach US$ 2,401.22 million by 2027 from US$ 1,252.66 million in 2019; it is estimated to grow at a CAGR of 8.8% from 2020 to 2027.
Increasing adoption of in-silico modelling tools in drug discovery, and increasing economic burden of drug discovery in the region are the key factors driving the growth of drug modelling software. However, less adoption in emerging countries is the major factor hindering the market growth in Asia Pacific.
Drug modelling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing key role in the development of novel drugs. Software based methods such as molecular modelling, structure-based drug design, structure-based virtual screening, ligand interaction and molecular dynamics are considered to be powerful tool for investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. In addition, appropriate implementation of these techniques may help in reducing cost of drug designing and development.
Artificial intelligence and associated technologies are making drug discovery cost-effective and quick. Leading biopharmaceutical companies have been utilizing AI platforms to accelerate the drug discovery of novel therapeutics. Various late-stage clinical trials fail due to ineffective drug targets. The integration of novel computational techniques such as artificial intelligence and cloud-based platforms within silico approaches is likely to revolutionize the overall drug discovery process. With the rapid introduction of AI in healthcare, numerous pharmaceutical companies have made investments in joint ventures with AI companies to develop better healthcare tools. These include the identification of drug targets and designing new drugs. At present, AI tools are used in screening, identifying compounds, as well as to minimize drug interactions that may cause issues later.
With the rapid introduction of AI in healthcare, numerous pharmaceutical companies have made investments in joint ventures with AI companies to develop better healthcare tools. These include the identification of drug targets and designing new drugs. Therefore, numerous partnerships between pharmaceutical industries and AI companies and government organizations were witnessed.
Moreover, a growing number of AI start-ups in drug discovery technologies is further accelerating the growth of the drug modelling software market. Exscientia, a start-up working with Sumitomo Dainippon Pharma (Japan), is using artificial intelligence to create an OCD drug, reduce the creation time from four years down to less than a year. In the field of mental health, this type of efficient drug discovery offers increased effectiveness in the treatment.
The 2019 novel coronavirus (2019-nCoV), officially named as COVID-19 by the WHO, has spread to more than 170 countries, including China prompting the WHO to declare the disease as a global pandemic. As research details emerge, the data pool grows exponentially, beyond the capacity of human intelligence alone to handle. Artificial intelligence (AI) is adept at identifying patterns from big data, and this piece will elucidate how it has become one of humanity’s ace cards in handling this crisis. Pune-based drug discovery research company Novalead will study the effectiveness of an anti- parasitic drug in the recovery of moderately ill Covid-19 patients. Hence, such outbreaks continue, the need for new technological advanced products nationwide increases and thereby positively impacting the market.
Rest of Asia Pacific Drug Modelling Software Market, Revenue and Forecast to 2027 (US$ Mn)
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
ASIA PACIFIC DRUG MODELLING SOFTWARE MARKET SEGMENTATION
By Product Type
- Database
- Software
- Others
By Application
- Drug Discovery and Development
- Computational Physiological Medicine
- Disease Modeling
- Medical Imaging
- Predictive Analysis of Drug Targets
- Simulation Software
- Cellular Simulation
- Others
By Country
- India
- China
- Japan
- South Korea
- Australia
Company Profiles
- Crown Bioscience Inc (JSR life science)
- Genedata AG
- Biognos AB
- Dassault Systèmes
- Acellera
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
roduct Type, Application, and Country
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Australia, China, Japan, South Korea
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Drug Modelling Software Market – By Product Type
1.3.2 Asia Pacific Drug Modelling Software Market – By Application
1.3.3 Asia Pacific Drug Modelling Software Market – By Country
2. Asia Pacific Drug Modelling Software Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Drug Modelling Software Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Drug Modelling Software Market - Asia Pacific PEST Analysis
4.3 Expert Opinion
5. Asia Pacific Drug Modelling Software Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Increasing Adoption of Modelling Tools in Drug Discovery
5.1.2 Increasing Economic Burden of Drug Discovery
5.2 Key Market Restraints
5.2.1 Less Adoption in Emerging Countries
5.3 Key Market Opportunities
5.3.1 Strategic Activities by Market Players
5.4 Future Trends
5.4.1 Growing Adoption of Artificial Intelligence in Drug Discovery
5.5 Impact analysis
6. Drug Modelling Software Market – Asia Pacific Analysis
6.1 Asia Pacific Drug Modelling Software Market Revenue Forecasts and Analysis
7. Asia Pacific Drug Modelling Software Market Analysis and Forecasts To 2027 – By Product Type
7.1 Overview
7.2 Asia Pacific Drug Modelling Software Market, By Product Type 2019 & 2027 (%)
7.2.1 Asia Pacific Drug Modelling Software Market Revenue and Forecasts to 2027, By Product Type (US$ Mn)
7.3 Database
7.3.1 Overview
7.3.2 Asia Pacific Database Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Software
7.4.1 Overview
7.4.1.1 Asia Pacific Software Revenue and Forecasts to 2027 (US$ Mn)
7.5 Other Product Types
7.5.1 Overview
7.5.2 Asia Pacific Other Product Types Market Revenue and Forecast to 2027 (US$ Mn)
8. Asia Pacific Drug Modelling Software Market Analysis and Forecasts To 2027 – By Application
8.1 Overview
8.2 Asia Pacific Drug Modelling Software Market, By Application 2019 & 2027 (%)
8.2.1 Asia Pacific Drug Modelling Software Market Revenue and Forecasts to 2027, By Application (US$ Mn)
8.3 Drug Discovery and Development
8.3.1 Overview
8.3.2 Asia Pacific Drug Discovery and Development Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Computational Physiological Medicine
8.4.1 Overview
8.4.2 Asia Pacific Computational Physiological Medicine Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Disease Modelling
8.5.1 Overview
8.5.2 Asia Pacific Disease Modelling Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Medical Imaging
8.6.1 Overview
8.6.2 Asia Pacific Medical Imaging Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Predictive Analysis of Drug Targets
8.7.1 Overview
8.7.2 Asia Pacific Predictive Analysis of Drug Targets Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Simulation Software
8.8.1 Overview
8.8.2 Asia Pacific Simulation Software Market Revenue and Forecasts to 2027 (US$ Mn)
8.9 Cellular Simulation
8.9.1 Overview
8.9.2 Asia Pacific Cellular Simulation Market Revenue and Forecasts to 2027 (US$ Mn)
8.10 Others
8.10.1 Overview
8.10.2 Asia Pacific Others Market Revenue and Forecasts to 2027 (US$ Mn)
9. Drug Modelling Software Market Revenue and Forecasts To 2027 – Geographical Analysis
9.1 Asia Pacific Drug modelling software Market Revenue and Forecasts To 2027
9.1.1 Overview
9.1.2 Asia-Pacific: Drug Modelling Software Market - Revenue and Forecast to 2027 (USD Million)
9.1.3 Asia-Pacific Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
9.1.4 Asia-Pacific Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
9.1.5 Asia-Pacific: Drug Modelling Software Market, by Country, 2019 & 2027 (%)
9.1.1 China: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.1.1 China: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.1.2 China Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
9.1.1.3 China Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
9.1.2 Japan: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.2.1 Japan: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.2.2 Japan Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
9.1.2.3 Japan Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
9.1.3 India: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.3.1 India: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.3.2 India Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
9.1.3.3 India Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
9.1.4 South Korea: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.4.1 South Korea: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.4.2 South Korea Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
9.1.4.3 South Korea Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
9.1.5 Australia: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.5.1 Australia: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
9.1.5.2 Australia Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
9.1.5.3 Australia Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
10. Impact of COVID-19 Pandemic on Asia Pacific Drug Modelling Software Market
10.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic
11. Company Profiles
11.1 Genedata AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Biognos AB
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Dassault Systèmes
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Acellera
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.5 Crown Bioscience Inc (JSR life science)
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
12. Appendix
12.1 About the Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Drug Modelling Software Market Revenue and Forecasts To 2027, By Product Type (US$ Mn)
Table 2. Asia Pacific Drug Modelling Software Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 3. Asia-Pacific Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 4. Asia-Pacific Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 5. China Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 6. China Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 7. Japan Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 8. Japan Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 9. India Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 10. India Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 11. South Korea Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 12. South Korea Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 13. Australia Drug Modelling Software Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 14. Australia Drug Modelling Software Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 15. Glossary of Terms, Drug Modelling Software Market
LIST OF FIGURES
Figure 1. Drug Modelling Software Market Segmentation
Figure 2. Asia Pacific Drug Modelling Software Market Overview
Figure 3. Software Segment Held Largest Share of Drug Modelling Software Market
Figure 4. India is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Asia Pacific Drug Modelling Software Market - Leading Country Markets (US$ Mn)
Figure 6. Drug Modelling Software Market - Asia Pacific PEST Analysis
Figure 7. Drug Modelling Software Market Impact Analysis of Driver and Restraints
Figure 8. Asia Pacific Drug Modelling Software Market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. Asia Pacific Drug Modelling Software Market, By Product Type 2019 & 2027 (%)
Figure 10. Asia Pacific Database Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. Asia Pacific Software Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Asia Pacific Other Product Types Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Asia Pacific Drug Modelling Software Market, By Application 2019 & 2027 (%)
Figure 14. Asia Pacific Drug Discovery and Development Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Asia Pacific Computational Physiological Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Asia Pacific Disease Modelling Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Asia Pacific Medical Imaging Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Asia Pacific Predictive Analysis of Drug Targets Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Asia Pacific Simulation Software Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Asia Pacific Cellular Simulation Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Asia Pacific Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Asia-Pacific: Drug Modelling Software Market, by Key Country– Revenue (2019) (USD Million)
Figure 23. Asia-Pacific Drug Modelling Software Market Revenue and Forecast to 2027 (USD Million)
Figure 24. Asia-Pacific: Drug Modelling Software Market, by Country, 2019 & 2027 (%)
Figure 25. China: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
Figure 26. Japan: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
Figure 27. India: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
Figure 28. South Korea: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
Figure 29. Australia: Drug Modelling Software Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Impact of COVID-19 Pandemic In Asia Pacific Country Markets
The List of Companies - Asia Pacific Drug Modelling Software Market
- Crown Bioscience Inc (JSR life science)
- Genedata AG
- Biognos AB
- Dassault Systèmes
- Acellera
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Asia Pacific Drug Modelling Software Market
Sep 2020
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Sep 2020
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2020
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Sep 2020
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Sep 2020
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Sep 2020
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Sep 2020
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)
Sep 2020